GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InMed Pharmaceuticals Inc (FRA:MWG0) » Definitions » EV-to-Revenue

InMed Pharmaceuticals (FRA:MWG0) EV-to-Revenue : -0.81 (As of Jun. 21, 2024)


View and export this data going back to 2004. Start your Free Trial

What is InMed Pharmaceuticals EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, InMed Pharmaceuticals's enterprise value is €-4.21 Mil. InMed Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was €5.19 Mil. Therefore, InMed Pharmaceuticals's EV-to-Revenue for today is -0.81.

The historical rank and industry rank for InMed Pharmaceuticals's EV-to-Revenue or its related term are showing as below:

FRA:MWG0' s EV-to-Revenue Range Over the Past 10 Years
Min: -5.32   Med: -1.03   Max: 29.69
Current: -0.8

During the past 13 years, the highest EV-to-Revenue of InMed Pharmaceuticals was 29.69. The lowest was -5.32. And the median was -1.03.

FRA:MWG0's EV-to-Revenue is ranked better than
93.91% of 1035 companies
in the Biotechnology industry
Industry Median: 7.54 vs FRA:MWG0: -0.80

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-06-21), InMed Pharmaceuticals's stock price is €0.2255. InMed Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was €1.15. Therefore, InMed Pharmaceuticals's PS Ratio for today is 0.20.


InMed Pharmaceuticals EV-to-Revenue Historical Data

The historical data trend for InMed Pharmaceuticals's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InMed Pharmaceuticals EV-to-Revenue Chart

InMed Pharmaceuticals Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 2.08 -1.31

InMed Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.36 -1.31 -0.87 -1.10 -0.75

Competitive Comparison of InMed Pharmaceuticals's EV-to-Revenue

For the Biotechnology subindustry, InMed Pharmaceuticals's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


InMed Pharmaceuticals's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, InMed Pharmaceuticals's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where InMed Pharmaceuticals's EV-to-Revenue falls into.



InMed Pharmaceuticals EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

InMed Pharmaceuticals's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=-4.211/5.194
=-0.81

InMed Pharmaceuticals's current Enterprise Value is €-4.21 Mil.
InMed Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €5.19 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


InMed Pharmaceuticals  (FRA:MWG0) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

InMed Pharmaceuticals's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=0.2255/1.151
=0.20

InMed Pharmaceuticals's share price for today is €0.2255.
InMed Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €1.15.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


InMed Pharmaceuticals EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of InMed Pharmaceuticals's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


InMed Pharmaceuticals (FRA:MWG0) Business Description

Traded in Other Exchanges
Address
815 West Hastings Street, Suite 310, Vancouver, BC, CAN, V6C 1B4
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based, and manufacturing of Pharmaceutical grade cannabinoids. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; and IntegraSyn which is a manufacturing system for Pharmaceutical-Grade Cannabinoids.

InMed Pharmaceuticals (FRA:MWG0) Headlines

No Headlines